Table 2 Clinical status of patients enrolled in the Limbe ART programme, 2002 to 2005
|
All patients [n(%), N = 2920] |
Patients enrolled before 1 Oct 2004 [n(%), N = 1487] |
Patients enrolled after 1 Oct 2004 [n(%), N = 1433] | |
|---|---|---|---|
| Final clinical status (as of 31 December 2005) | |||
| In care | 1597 (54.7) | 663 (44.6) | 934 (65.2) |
| Lost to follow up | 1149 (39.3) | 715 (48.1) | 434 (30.3) |
| Dead | 164 (5.6) | 104 (7.0) | 60(4.2) |
| Transferred | 10 (0.3) | 5 (0.3) | 5 (0.3) |
| Adhering to ART clinic visits | |||
| < 80% (non-adherence) | 2260 (77.4) | 1286 (86.5) | 974 (68.0) |
| 80-94% (poor adherence) | 365 (12.5) | 158 (10.6) | 207 (14.4) |
| > 94% (good adherence) | 295 (10.1) | 43 (2.9) | 252 (17.6) |
| Dropped out of care immediately after ART initiation | |||
| Yes | 631 (21.6) | 295 (19.8) | 336 (23.5) |
| No | 2289 (78.4) | 1192 (80.2) | 1097 (76.5) |
| Tuberculosis co-infection at the beginning or during the course of ART | |||
| Yes | 35 (1.2) | 20 (1.3) | 15 (1.01) |
| No | 2885 (98.8) | 1467 (98.6) | 1418 (98.9) |
| Median entry CD4 count, cells/mm 3 (range) | 107 (0-1696) | 101 (0-1696) | 111 (0-958) |
| Entry CD4 count, (cells/mm 3 )* | |||
| 0-99 | 1287 (47.4) | 659 (49.1) | 628 (45.7) |
| > 100 | 1428 (52.6) | 682 (50.9) | 746 (54.3) |
| Treatment regimen on enrolment* | |||
| Stavudine/lamivudine/nevirapine | 2752 (94.7) | 1390 (94.3) | 1362 (95.0) |
| Stavudine/lamivudine/efavirenz | 40 (1.4) | 32 (2.2) | 8 (0.6) |
| Zidovudine/lamivudine/nevirapine | 25 (0.9) | 4 (0.3) | 21 (1.5) |
| Zidovudine/lamivudine/efavirenz | 82 (2.8) | 40 (2.7) | 42 (2.9) |
| Stavudine/lamivudine/indinavir | 5 (0.2) | 5 (0.3) | 0 |
| Zidovudine/lamivudine/indinavir | 3 (0.1) | 3 (0.2) | 0 |